IN191236B - - Google Patents

Info

Publication number
IN191236B
IN191236B IN775DE1999A IN191236B IN 191236 B IN191236 B IN 191236B IN 775DE1999 A IN775DE1999 A IN 775DE1999A IN 191236 B IN191236 B IN 191236B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Yatendra Kumar
Rajesh Kumar Thaper
Sarioi Madhava Dileep Kumar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11091180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN191236(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN775DE1999 priority Critical patent/IN191236B/en
Priority to BR0010923-1A priority patent/BR0010923A/pt
Priority to ES00900300T priority patent/ES2284472T3/es
Priority to EP00900300A priority patent/EP1185264B1/en
Priority to US09/979,475 priority patent/US6528660B1/en
Priority to PCT/IB2000/000014 priority patent/WO2000071116A1/en
Priority to AU19967/00A priority patent/AU778962B2/en
Priority to DK00900300T priority patent/DK1185264T3/da
Priority to AT00900300T priority patent/ATE362759T1/de
Priority to PT00900300T priority patent/PT1185264E/pt
Priority to CNB008080275A priority patent/CN1196679C/zh
Priority to CNA2005100525833A priority patent/CN1680315A/zh
Priority to DE60034946T priority patent/DE60034946T2/de
Priority to MYPI20002283A priority patent/MY133511A/en
Priority to ZA200109656A priority patent/ZA200109656B/en
Priority to HK02106699.9A priority patent/HK1045118A1/zh
Priority to US10/378,574 priority patent/US20030149279A1/en
Publication of IN191236B publication Critical patent/IN191236B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN775DE1999 1999-05-25 1999-05-25 IN191236B (no)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IN775DE1999 IN191236B (no) 1999-05-25 1999-05-25
DE60034946T DE60034946T2 (de) 1999-05-25 2000-01-06 Verfahren zur herstellung von amorphem atorvastatin kalzium
AT00900300T ATE362759T1 (de) 1999-05-25 2000-01-06 Verfahren zur herstellung von amorphem atorvastatin kalzium
CNB008080275A CN1196679C (zh) 1999-05-25 2000-01-06 无定形阿托伐斯汀钙的制备方法
EP00900300A EP1185264B1 (en) 1999-05-25 2000-01-06 Process for the production of amorphous atorvastatin calcium
US09/979,475 US6528660B1 (en) 1999-05-25 2000-01-06 Process for the production of amorphous atorvastatin calcium
PCT/IB2000/000014 WO2000071116A1 (en) 1999-05-25 2000-01-06 Process for the production of amorphous atorvastatin calcium
AU19967/00A AU778962B2 (en) 1999-05-25 2000-01-06 Process for the production of amorphous atorvastatin calcium
DK00900300T DK1185264T3 (da) 1999-05-25 2000-01-06 Fremgangsmåde til fremstilling af amorft atorvastatin-calcium
BR0010923-1A BR0010923A (pt) 1999-05-25 2000-01-06 Processo para a produção de atorvastatina de cálcio amorfa
PT00900300T PT1185264E (pt) 1999-05-25 2000-01-06 Processo para a produção de atorvastatina de cálcio amorfa
ES00900300T ES2284472T3 (es) 1999-05-25 2000-01-06 Procedimiento para la produccion de atorvastatina clacica amorfa.
CNA2005100525833A CN1680315A (zh) 1999-05-25 2000-01-06 无定形阿托伐斯汀钙的制备方法
MYPI20002283A MY133511A (en) 1999-05-25 2000-05-24 Process for the production of amorphous atorvastatin calcium
ZA200109656A ZA200109656B (en) 1999-05-25 2001-11-23 Process for the production of amorphous atorvastatin calcium.
HK02106699.9A HK1045118A1 (zh) 1999-05-25 2002-09-12 無定形的阿伐他汀鈣的製備方法
US10/378,574 US20030149279A1 (en) 1999-05-25 2003-03-03 Process for the production of amorphous atorvastatin calcium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN775DE1999 IN191236B (no) 1999-05-25 1999-05-25

Publications (1)

Publication Number Publication Date
IN191236B true IN191236B (no) 2003-10-11

Family

ID=11091180

Family Applications (1)

Application Number Title Priority Date Filing Date
IN775DE1999 IN191236B (no) 1999-05-25 1999-05-25

Country Status (15)

Country Link
US (2) US6528660B1 (no)
EP (1) EP1185264B1 (no)
CN (2) CN1680315A (no)
AT (1) ATE362759T1 (no)
AU (1) AU778962B2 (no)
BR (1) BR0010923A (no)
DE (1) DE60034946T2 (no)
DK (1) DK1185264T3 (no)
ES (1) ES2284472T3 (no)
HK (1) HK1045118A1 (no)
IN (1) IN191236B (no)
MY (1) MY133511A (no)
PT (1) PT1185264E (no)
WO (1) WO2000071116A1 (no)
ZA (1) ZA200109656B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
IN190564B (no) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
MXPA03010266A (es) * 2001-06-29 2004-03-10 Warner Lambert Co Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
AU2001284385A1 (en) * 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
EA013500B1 (ru) * 2003-04-11 2010-06-30 Лек Фармасьютиклз Д.Д. Способ получения аморфной кальциевой соли аторвастатина
AU2004234057A1 (en) * 2003-04-29 2004-11-11 Akzo Nobel N.V. Antisolvent solidification process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
SI1727795T1 (sl) 2004-03-17 2012-05-31 Ranbaxy Lab Ltd Postopek za pripravo atorvastatin kalcija v amorfni obliki
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
JP2007532622A (ja) * 2004-04-16 2007-11-15 ファイザー・プロダクツ・インク 非晶質アトルバスタチン・カルシウムの形成方法
BRPI0510713A (pt) 2004-05-05 2007-11-20 Pfizer Prod Inc formas de sal de ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-diidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)ca rbonil]-1h-pirrol-1- heptanóico
EP1771455B1 (en) * 2004-07-16 2016-05-11 LEK Pharmaceuticals d.d. Oxidative degradation products of atorvastatin calcium
WO2006011041A2 (en) 2004-07-20 2006-02-02 Warner-Lambert Company Llc Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
EP1784389A4 (en) 2004-08-27 2009-03-25 Biocon Ltd PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM
MX2007004425A (es) * 2004-10-18 2007-06-07 Teva Pharma Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.
CN101048141A (zh) 2004-10-28 2007-10-03 沃尼尔·朗伯有限责任公司 形成非晶形的阿托伐他汀的方法
WO2006048888A1 (en) * 2004-11-01 2006-05-11 Jubilant Organosys Limited Novel process for the preparation of amorphous atorvastatin calcium salt
CA2588216A1 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
WO2007052296A2 (en) * 2005-08-23 2007-05-10 Kopran Research Laboratories Ltd A process of preparing amorphous atorvastatin calcium
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ES2304335T3 (es) * 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
US20100204195A1 (en) * 2007-07-27 2010-08-12 Cipla Limited Pharmaceutical Compositions and Process for Making Them
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101684090B (zh) * 2008-09-27 2012-12-05 广东东阳光药业有限公司 一种制备无定形阿托伐他汀钙的方法
US8115015B2 (en) 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
WO2016055934A1 (en) * 2014-10-09 2016-04-14 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44680B (en) 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IL122118A (en) * 1995-07-17 1999-07-14 Warner Lambert Co Crystalline form I atorvastatin pharmaceutical compositions containing it and process for its preparation
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina

Also Published As

Publication number Publication date
DK1185264T3 (da) 2007-08-20
AU1996700A (en) 2000-12-12
ATE362759T1 (de) 2007-06-15
ES2284472T3 (es) 2007-11-16
CN1196679C (zh) 2005-04-13
EP1185264B1 (en) 2007-05-23
DE60034946D1 (de) 2007-07-05
DE60034946T2 (de) 2008-01-17
WO2000071116A1 (en) 2000-11-30
US6528660B1 (en) 2003-03-04
US20030149279A1 (en) 2003-08-07
PT1185264E (pt) 2007-07-10
EP1185264A1 (en) 2002-03-13
BR0010923A (pt) 2002-07-16
MY133511A (en) 2007-11-30
ZA200109656B (en) 2002-06-27
CN1351493A (zh) 2002-05-29
CN1680315A (zh) 2005-10-12
HK1045118A1 (zh) 2002-11-15
AU778962B2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
BE2018C020I2 (no)
BE2015C057I2 (no)
BE2016C007I2 (no)
BE2015C018I2 (no)
BE2014C017I2 (no)
BE2013C051I2 (no)
BE2013C020I2 (no)
BE2013C015I2 (no)
BE2013C001I2 (no)
BE2012C036I2 (no)
BE2011C004I2 (no)
BE2010C011I2 (no)
BE2008C046I2 (no)
BE1025464I2 (no)
BRPI0017527B8 (no)
BE2008C047I2 (no)
BRPI0001672A2 (no)
IN191236B (no)
BRPI0001542A2 (no)
JP2002510068A5 (no)
JP2002519896A5 (no)
JP2002532981A5 (no)
BRPI0012675B8 (no)
BRPI0017522A2 (no)
BRMU7902607U2 (no)